New pill shows promise for ulcerative colitis sufferers
NCT ID NCT05291689
First seen Mar 25, 2026 · Last updated May 12, 2026 · Updated 11 times
Summary
This study tested an experimental drug called MORF-057 in 39 adults with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. The goal was to see if the drug could reduce gut inflammation and improve symptoms over 12 weeks. Participants took the pill by mouth, and researchers measured changes using colon tissue samples and symptom scores.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Study Site
Tampa, Florida, 33609, United States
-
Clinical Study Site
Lafayette, Louisiana, 70503, United States
-
Clinical Study Site
Freehold, New Jersey, 07728, United States
-
Clinical Study Site
Brooklyn, New York, 11235, United States
-
Clinical Study Site
New York, New York, 10075, United States
-
Clinical Study Site
Bydgoszcz, 85-794, Poland
-
Clinical Study Site
Elblag, 82-300, Poland
-
Clinical Study Site
Katowice, 40-748, Poland
-
Clinical Study Site
Lodz, 90-349, Poland
-
Clinical Study Site
Lodz, 90-752, Poland
-
Clinical Study Site
Oświęcim, 32-600, Poland
-
Clinical Study Site
Sopot, 81-756, Poland
-
Clinical Study Site
Sosnowiec, 41-209, Poland
-
Clinical Study Site
Staszów, 28-200, Poland
-
Clinical Study Site
Tychy, 43-100, Poland
-
Clinical Study Site
Warsaw, 00-728, Poland
-
Clinical Study Site
Warsaw, 02-665, Poland
Conditions
Explore the condition pages connected to this study.